Release of Part 1 of EXPOSED scheduled for the week of May 20. EXPOSED is a four-part series of short films that tell the story of the deadly global epidemic of tuberculosis. The series will portray the struggles of four inspiring individuals – an MDR-TB survivor, a TB doctor, a clinical trial volunteer, and a TB vaccine researcher – bringing viewers to the forefront of the race against tuberculosis.
This week we highlight an interview with Dr. Andrew Vernon, the Chief, Clinical Research Branch, Division of Tuberculosis Elimination at the U.S. Centers for Disease Control and Prevention (CDC). He discusses the progress made in TB drug development and the growing number of TB trials and trials groups.
On September 5 and 6, 2012, the “Demystifying Pyrazinamide – Challenges and Opportunities” Workshop will be held at Johns Hopkins University and is sponsored by National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, Johns Hopkins University Center for AIDS Research, and the Stop TB Partnership Working Group on New Drugs. There will be live streaming available.
Yesterday, efficacy data from the first novel regimen trial (NC001) were published in the Lancet. The results found that the regimen containing PA-824, moxifloxacin, and pyrazinamide, could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments. Link to article, press release, and related video are included. Additional links to TB R&D news are also included.